CHF 500’000 for Xsensio in Western Switzerland

FIT | 04 February 2019

Founded in 2014, Xsensio develops the Lab-on-SkinTM ultra-miniaturized sensing platform to extend the functionality of next-generation wearable devices with continuous monitoring of biochemical parameters on the skin’s surface to provide unique, real-time information about our health and well-being.

Developed in collaboration with the Nanoelectronic Devices Laboratory of EPFL (Nanolab) led by Prof. Adrian Ionescu, the system continuously collects sweat, based simply on microcapillarity forces, then reads and analyzes its composition in real time, all on a single chip measuring 25 square millimeters. The device can contain on a miniaturized size a very large number of ultra-sensitive sensors. The Lab-on-SkinTM platform offers great modularity thanks to the ability to modify the miniature sensors of the chip when depositing different biochemical layers. Thus, Xsensio can measure a multitude of biomarkers ranging from electrolytes and metabolites to molecules and proteins. Users will enjoy real-time personalized data, which will allow them to detect dehydration, fatigue or muscle cramps, for example, or even later to inform them about disease risk factors.

“This financial support comes at a key moment for our company. Destined for commercial development purposes, the FIT funds will allow us to advance in the commercialization of our sensing platform with pharmaceutical and technological companies as partners and accelerate our growth. Says Esmeralda Megally, CEO and co-founder of Xsensio, after the FIT jury session in December.

The startup counts in its Board of Advisors personalities such as Bracken Darrell, CEO and President of Logitech, or Professor Emeritus Denis Hochstrasser, former Vice-Rector and Vice-President of the University of Geneva, in charge of the Biotech Campus. In January 2019, Xsensio, along with 10 other EPFL startups, exhibited its pioneering technology in the first edition of the Swiss pavilion at CES 2019 in Las Vegas.

Esmeralda Megally, CEO
Tél. +41 79 138 89 06
Email :